Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05726864 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05726864 · ClinicalTrials.gov record · last posted 2026-07-10

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Study acronym: AMPLIFY-7P
StatusActive, Not Recruiting
PhasePhase 1/2
Started2023-04-14
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides 7P\]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtained with related product ELI-002 2P, which was studied in protocol ELI-002-001 under IND 26909.

Protocol amendment history 1 change detected by DataLookout

2026-07-11
Primary completion moved earlier: 2026-11 → 2026-04-20
Trial Details
NCT Number NCT05726864
Lead Sponsor Elicio Therapeutics
Conditions Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S +6 more
Enrollment 158 participants
Start Date 2023-04-14
Primary Completion 2026-04-20 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-10